A Pilot Study of Pioglitazone Treatment for Nonalcoholic Steatohepatitis

Hepatology

Volumn 39, Issue 1, 2004, Pages 188-196

  Promrat, Kittichai ^a   Lutchman, Glen ^a   Uwaifo, Gabriel I ^b   Freedman, Renee J ^b   Soza, Alejandro ^a   Heller, Theo ^a   Doo, Edward ^a   Ghany, Marc ^a   Premkumar, Ahalya ^d   Park, Yoon ^a   Liang, T Jake ^a   Yanovski, Jack A ^b   Kleiner, David E ^c   Hoofnagle, Jay H ^a,e  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e Bldg 31 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FATTY ACID; GLUCOSE; INSULIN SENSITIZING AGENT; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT DISORDER; CELL DAMAGE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PARENCHYMA; LIVER SIZE; MALE; MALLORY BODY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; GLUCOSE TOLERANCE TEST; HEPATITIS; MIDDLE AGED;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FATTY LIVER; FEMALE; GLUCOSE TOLERANCE TEST; HEPATITIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 1442355447     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20012     Document Type: Article

References (35)

1. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
4. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-79.
5. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of fotty-two patients for up to 21 years. HEPATOLOGY 1990;11:74-80.
6. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. HEPATOLOGY 1990;12:1106-10.
7. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. HEPATOLOGY 1995;22:1714-1719.
8. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. HEPATOLOGY 1999;29:664-669
9. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
10. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999;353:1634-1636.
11. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002;50:585-588.
12. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
13. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
14. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
15. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
16. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-894.
17. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
18. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligaiid rosiglitazone. HEPATOLOGY 2003;38:1008-1017.
19. Sanyal AJ, Contos MJ, Sargeant M, Stravitz RT, Luketic VA, Sterling RK, Shiffman ML, et al. A randomized controlled pilot study of pioglitazone and vitamin E versus Vitamin E for nonalcoholic steatohepatitis [abstract]. HEPATOLOGY 2002;36(suppl):875A.
20. The Food Guide Pyramid. Washington, DC: Department of Agriculture, Center for Nutrition Policy and Promotion; 1996. Home and Garden Bulletin No. 252.
21. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Manual. Champaign, IL: Human Kinetics Publishers, Inc., 1988:1-177.
22. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series, No. 727. Geneva: World Health Organization, 1985;1-113.
23. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes 1989;38:1512-1527.
24. Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 1997;15:287-293.
25. Levenson H, Greensite F, Hoefs J, Friloux L, Applegate G, Silva E, Kanel G, et al. Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5 T vs biopsy. AJR Am J Roentgenol 1991;156:307-312.
26. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-873.
27. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101:1354-1361.
28. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002;8:1122-1128.
29. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802.
30. Lindor KD. UDCAsol; NASH Study Group. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized, placebo-controlled trial [abstract]. Gastroenterology 2003;124(suppl):336A.
31. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
33. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.
34. Nair S, Diehl AM, Perrillo R. Metformin in nonalcoholic steatohepatitis (NASH): efficacy and safety, a preliminary report [abstract]. Gastroenterology 2002;122(Suppl):4A.
35. Fuller NJ, Laskey MA, Elia M. Assessment of the composition of major body regions by dual-energy X-ray absorptiometry (DEXA), with special reference to limb muscle mass. Clin Physiol 1992;12:253-266.